Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin d may cut risk of repeat preeclampsia in High-Risk pregnancies

NCT ID NCT07717931

Prevention Sponsor: CMH Multan Institute of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether taking a daily vitamin D supplement (4000 IU) can lower the chance of preeclampsia returning in pregnant women who have had it before. Researchers will randomly assign 146 women to receive either vitamin D or a placebo from enrollment until 36 weeks of pregnancy. Participants attend check-ups every two weeks for blood pressure monitoring and have vitamin D levels measured monthly to watch for toxicity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vitamin D (cholecalciferol) 4000 IU taken orally once daily
What this could lead to
If effective, daily vitamin D could become a simple, low-cost way to prevent preeclampsia in women who have had it before.
What could go wrong
This is a single-center trial with 146 participants, so results may not apply to all populations. Vitamin D can be toxic at high doses, and the benefit over placebo is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

146 people

The number who actually took part.

Started

Aug 2025

Finished

Jan 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant women * Singleton pregnancy (on USG) * Gestational age ≥ 24-weeks (on LMP method) and * Past medical history of pre-eclampsia (on medical record) Exclusion Criteria: * Pre-existing chronic hypertension * Cardiac diseases (congenital or acquired) * Renal disease * Thyrotoxicosis (on history and medical record) and * Intra-uterine death of the fetus.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Preeclampsia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertension, pregnancy-induced preeclampsia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Preeclampsia

Contacts and locations

Locations

  • CMH Multan Institute of Medical Sciences

    Multan, Punjab Province, 60000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.